83 results
DEFA14A
APGN
Apexigen Inc
16 Aug 23
Additional proxy soliciting materials
8:00am
☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
☐ Definitive Proxy Statement
☒ Definitive Additional Materials … materials.
☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.
UNITED STATES
SECURITIES
DEFM14A
APGN
Apexigen Inc
30 Jun 23
Proxy related to merger
4:21pm
☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
☒ Definitive Proxy Statement
☐ Definitive Additional Materials … materials.
☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.
PROXY STATEMENT OF APEXIGEN, INC
425
PYXS
Pyxis Oncology Inc
25 May 23
Business combination disclosure
8:14am
expenses.
The Apexigen team has done a great job of already getting clinical materials ready for even Phase III. So that expense has already been
425
EX-99.1
APGN
Apexigen Inc
24 May 23
Business combination disclosure
4:55pm
statements will be achieved or occur. Except as set forth in the definitive merger agreement or in any proxy solicitation materials, Pyxis Oncology … statement/prospectus and other relevant materials to be filed with the SEC regarding the proposed transaction when such materials become available
425
9dpnz8k01 fxu
24 May 23
Business combination disclosure
7:05am
8-K
EX-2.1
ye1jq zz894po3
24 May 23
Pyxis Oncology to Acquire Apexigen
7:02am
424B3
1l7rt4o1u2mlx 6nb05
10 Apr 23
Prospectus supplement
4:03pm
424B3
36nnx1a0vazk 3ddrldb
10 Apr 23
Prospectus supplement
4:02pm
POS AM
k6pnt2btoai 5nou
4 Apr 23
Prospectus update (post-effective amendment)
4:24pm
POS AM
ra82jyau5mppug95r
4 Apr 23
Prospectus update (post-effective amendment)
4:23pm
424B3
u2vflyropnzmqr6p1
9 Sep 22
Prospectus supplement
4:40pm
424B3
z2z0ns ky5v80
9 Sep 22
Prospectus supplement
4:38pm